{"id":"capecitabine-and-mitomycin-c","safety":{"commonSideEffects":[{"rate":"27%","effect":"Hand-foot syndrome"},{"rate":"21%","effect":"Diarrhea"},{"rate":"17%","effect":"Fatigue"},{"rate":"14%","effect":"Nausea"},{"rate":"10%","effect":"Vomiting"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Capecitabine is converted to 5-fluorouracil, which inhibits thymidylate synthase. Mitomycin C cross-links DNA, preventing DNA replication and transcription.","oneSentence":"Capecitabine is a thymidylate synthase inhibitor, and Mitomycin C is an alkylating agent.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:07:44.563Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Colorectal cancer"},{"name":"Breast cancer"}]},"trialDetails":[{"nctId":"NCT04929028","phase":"PHASE2","title":"Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-08-09","conditions":"AIDS-Related Anal Carcinoma, Anal Margin Squamous Cell Carcinoma, Anal Non-Keratinizing Squamous Cell Carcinoma","enrollment":40},{"nctId":"NCT02758951","phase":"PHASE2, PHASE3","title":"Perioperative Systemic Therapy for Isolated Resectable Colorectal Peritoneal Metastases","status":"ACTIVE_NOT_RECRUITING","sponsor":"Koen Rovers","startDate":"2017-06-01","conditions":"Colorectal Neoplasm, Colorectal Cancer, Colorectal Neoplasms Malignant","enrollment":358},{"nctId":"NCT04166318","phase":"PHASE2","title":"Lower-Dose Chemoradiation in Treating Patients With Early-Stage Anal Cancer, the DECREASE Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2020-01-02","conditions":"Anal Basaloid Carcinoma, Anal Canal Cloacogenic Carcinoma, Anal Canal Squamous Cell Carcinoma","enrollment":252},{"nctId":"NCT07425054","phase":"PHASE2","title":"HPV ctDNA Response-Adapted Chemoradiation +/- Retifanlimab Treatment in Advanced-Stage Anal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Jennifer Dorth","startDate":"2026-03","conditions":"Anal Cancer, HPV-Related Carcinoma, Squamous Cell Carcinoma of the Anus","enrollment":33},{"nctId":"NCT05838391","phase":"NA","title":"Adaptive Radiation in Anal Cancer","status":"RECRUITING","sponsor":"Columbia University","startDate":"2023-05-18","conditions":"Anal Squamous Cell Carcinoma","enrollment":20},{"nctId":"NCT05902533","phase":"PHASE2, PHASE3","title":"REDEL Trial: Reduced Elective Nodal Dose for Anal Cancer Toxicity Mitigation","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Cincinnati","startDate":"2023-08-14","conditions":"Anal Cancer","enrollment":33},{"nctId":"NCT07043543","phase":"NA","title":"Evaluation of the Clinical Utility of Online Adaptive Radiotherapy in Bladder Cancer (BLADAPT-GETUG V11)","status":"NOT_YET_RECRUITING","sponsor":"Institut du Cancer de Montpellier - Val d'Aurelle","startDate":"2026-01-15","conditions":"Bladder Cancer","enrollment":120},{"nctId":"NCT06207981","phase":"PHASE3","title":"Phase III Study Evaluating Induction Chemotherapy Followed by Chemoradiotherapy Compared to Standard Chemoradiotherapy for Locally Advanced SCCA","status":"RECRUITING","sponsor":"Federation Francophone de Cancerologie Digestive","startDate":"2024-02-26","conditions":"Anal Cancer","enrollment":310},{"nctId":"NCT04046133","phase":"PHASE1","title":"Phase 1b/II Trial of Pembrolizumab Plus IMRT in Stage III/IV Carcinoma of Anus","status":"ACTIVE_NOT_RECRUITING","sponsor":"Cardiff University","startDate":"2020-10-19","conditions":"Anal Cancer Stage III A, Anal Cancer Stage III B","enrollment":52},{"nctId":"NCT02299999","phase":"PHASE2","title":"SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNICANCER","startDate":"2014-04-07","conditions":"Metastatic Breast Cancer","enrollment":1460},{"nctId":"NCT01167725","phase":"PHASE3","title":"Standard Therapy With or Without Surgery and Mitomycin C in Treating Patients With Advanced Limited Peritoneal Dissemination of Colon Cancer","status":"TERMINATED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2010-08","conditions":"Colorectal Cancer","enrollment":340},{"nctId":"NCT04719988","phase":"PHASE2","title":"Anti-PD-1 and mDCF Followed by Chemoradiotherapy in Patients With Stage III Squamous Cell Anal Carcinoma.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centre Hospitalier Universitaire de Besancon","startDate":"2022-01-04","conditions":"Squamous Cell Carcinoma of the Anus Stage III","enrollment":55},{"nctId":"NCT03844256","phase":"PHASE1, PHASE2","title":"A Study of Mitomycin-c/ Capecitabine ChemoRadiotherapy Combined With Nivolumab Monotherapy or Ipilumimab and Nivolumab, as Bladder Sparing Curative Treatment for Muscle Invasive Bladder Cancer: the CRIMI Study","status":"RECRUITING","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2019-01-07","conditions":"Urinary Bladder Cancer, Invasive Bladder Cancer","enrollment":50},{"nctId":"NCT02158988","phase":"PHASE3","title":"Cytoreductive Surgery (CRS) With/Without HIPEC in Gastric Cancer With Peritoneal Carcinomatosis","status":"COMPLETED","sponsor":"Charite University, Berlin, Germany","startDate":"2014-03-01","conditions":"Malignant Neoplasm of Stomach, Secondary Malignant Neoplasm of Peritoneum, Secondary Malignant Neoplasm of Other and Unspecified Sites","enrollment":105},{"nctId":"NCT02526953","phase":"PHASE3","title":"Efficacy Study of Chemoradiotherapy With or Without Paclitaxel in Squamous-cell Anal Carcinoma Patients","status":"UNKNOWN","sponsor":"Blokhin's Russian Cancer Research Center","startDate":"2016-01","conditions":"Anus Neoplasms, Carcinoma, Squamous Cell, Anus Diseases","enrollment":314},{"nctId":"NCT04370925","phase":"PHASE3","title":"Efficacy of HIPEC in Patients With Colorectal Cancer at High Risk of Peritoneal Carcinomatosis","status":"RECRUITING","sponsor":"Affiliated Cancer Hospital & Institute of Guangzhou Medical University","startDate":"2020-06-04","conditions":"Colorectal Cancer","enrollment":688},{"nctId":"NCT00276744","phase":"PHASE2","title":"Individualized Drug Treatment for Treating Patients With Pancreatic Cancer","status":"TERMINATED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2005-10","conditions":"Pancreatic Cancer","enrollment":249},{"nctId":"NCT01705002","phase":"PHASE1","title":"Intravenously Administered Pegylated Liposomal Mitomycin-C Lipid-based Prodrug (PROMITIL) in Cancer Patients With Solid Tumors.","status":"COMPLETED","sponsor":"Lipomedix Pharmaceuticals Inc.","startDate":"2012-10","conditions":"Cancer, Solid Tumor, Metastatic Colorectal Cancer (mCRC)","enrollment":88},{"nctId":"NCT03381352","phase":"PHASE2","title":"Study of IMRT Radiotherapy Concurrent Chemothrerapy for Anal Cancer","status":"UNKNOWN","sponsor":"Chinese Academy of Medical Sciences","startDate":"2015-12-02","conditions":"Anal Cancer","enrollment":27},{"nctId":"NCT01843452","phase":"PHASE2","title":"Phase II Study of Concomitant Intensity-modulated Radiotherapy Combined to Capecitabine, Mitomycin and Panitumumab in Patients With Stage II-IIIB Squamous-cell Carcinoma of the Anal Canal","status":"TERMINATED","sponsor":"Centre Hospitalier Universitaire Vaudois","startDate":"2012-12","conditions":"Carcinoma of Anal Canal","enrollment":8},{"nctId":"NCT01530503","phase":"PHASE2","title":"Second Line Therapy in Advanced Biliary Tract Cancer","status":"COMPLETED","sponsor":"IRCCS San Raffaele","startDate":"2011-11","conditions":"Biliary Tract Cancer","enrollment":52},{"nctId":"NCT01703910","phase":"PHASE2","title":"Study of Individualized Therapies Selection for Patients With Metastatic Colorectal Carcinoma According to the Therapeutic","status":"COMPLETED","sponsor":"Centro Nacional de Investigaciones Oncologicas CARLOS III","startDate":"2012-11","conditions":"Adenocarcinoma of Colon, Adenocarcinoma of Rectum, Metastatic Disease","enrollment":29},{"nctId":"NCT01941966","phase":"PHASE2","title":"A Study of Substitution of 5-FU (Fluorouracil) by Capecitabine in Scheme of Chemo-radiotherapy in Patients With Squamous Cell Carcinoma of the Anal Canal.","status":"COMPLETED","sponsor":"Instituto do Cancer do Estado de São Paulo","startDate":"2010-11","conditions":"Anal Canal Cancer.","enrollment":51},{"nctId":"NCT01196455","phase":"PHASE2","title":"Capecitabine and Mitomycin C in Treatment of Patients With Metastatic Breast Cancer","status":"UNKNOWN","sponsor":"Croatian Cooperative Group for Clinical Research in Oncology","startDate":"2006-03","conditions":"Breast Cancer, Metastasis","enrollment":39},{"nctId":"NCT00294359","phase":"PHASE2, PHASE3","title":"The MAX Study: Mitomycin C, Avastin and Xeloda in Patients With Untreated Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Australasian Gastro-Intestinal Trials Group","startDate":"2005-06","conditions":"Metastatic Colorectal Cancer","enrollment":333}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Capecitabine (Xeloda)","Mitomycin C (Mutamycin)"],"phase":"phase_2","status":"active","brandName":"Capecitabine and Mitomycin C","genericName":"Capecitabine and Mitomycin C","companyName":"Croatian Cooperative Group for Clinical Research in Oncology","companyId":"croatian-cooperative-group-for-clinical-research-in-oncology","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Capecitabine is a small molecule thymidylate synthase inhibitor used in the treatment of various cancers, including metastatic colorectal cancer. Mitomycin C is an inhibitor used in the treatment of anal cancers, such as anal basaloid carcinoma, anal canal cloacogenic carcinoma, anal canal squamous cell carcinoma, and anal margin squamous cell carcinoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}